S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Graphite Shortage Story You're Not Being Told (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Is Graphite the New Lithium? (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
Is Graphite the New Lithium? (Ad)
Okta, Inc: When Great Results Aren’t Good Enough 
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Graphite Shortage Story You're Not Being Told (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Is Graphite the New Lithium? (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
Is Graphite the New Lithium? (Ad)
Okta, Inc: When Great Results Aren’t Good Enough 
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Graphite Shortage Story You're Not Being Told (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Is Graphite the New Lithium? (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
Is Graphite the New Lithium? (Ad)
Okta, Inc: When Great Results Aren’t Good Enough 
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Graphite Shortage Story You're Not Being Told (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Is Graphite the New Lithium? (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
Is Graphite the New Lithium? (Ad)
Okta, Inc: When Great Results Aren’t Good Enough 
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
NASDAQ:PHAS

PhaseBio Pharmaceuticals (PHAS) Stock Forecast, Price & News

$0.0006
0.00 (0.00%)
(As of 05/31/2023 ET)
Compare
Today's Range
$0.0006
$0.0006
50-Day Range
N/A
52-Week Range
$0.07
$4.08
Volume
5,810 shs
Average Volume
848,888 shs
Market Capitalization
$29,914.80
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

PhaseBio Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
749,900.0% Upside
$4.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars


PHAS stock logo

About PhaseBio Pharmaceuticals (NASDAQ:PHAS) Stock

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.

Receive PHAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PhaseBio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHAS Stock News Headlines

8-K: PhaseBio Pharmaceuticals Inc
The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
PhaseBio Files for Bankruptcy With Plans to Sell Assets
See More Headlines

PHAS Price History

PHAS Company Calendar

Last Earnings
11/10/2021
Today
6/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PHAS
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.50
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+749,900.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-131,070,000.00
Net Margins
-12,572.13%
Pretax Margin
-12,572.13%

Debt

Sales & Book Value

Annual Sales
$818,000.00
Book Value
($1.93) per share

Miscellaneous

Free Float
44,922,000
Market Cap
$29,914.80
Optionable
Not Optionable
Beta
2.57

Key Executives

  • Jonathan P. Mow
    Chief Executive Officer & Director
  • John P. Sharp
    Chief Financial Officer
  • John S. Lee
    Chief Medical Officer
  • Kristopher L. Hanson
    Secretary, Senior VP & General Counsel
  • Susan E. Arnold
    Senior Vice President-Technical Operations













PHAS Stock - Frequently Asked Questions

Should I buy or sell PhaseBio Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PHAS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PHAS, but not buy additional shares or sell existing shares.
View PHAS analyst ratings
or view top-rated stocks.

What is PhaseBio Pharmaceuticals' stock price forecast for 2023?

5 analysts have issued 1-year price objectives for PhaseBio Pharmaceuticals' shares. Their PHAS share price forecasts range from $1.00 to $8.00. On average, they anticipate the company's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 749,900.0% from the stock's current price.
View analysts price targets for PHAS
or view top-rated stocks among Wall Street analysts.

How have PHAS shares performed in 2023?

PhaseBio Pharmaceuticals' stock was trading at $0.0301 at the start of the year. Since then, PHAS shares have decreased by 98.0% and is now trading at $0.0006.
View the best growth stocks for 2023 here
.

How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by $0.07. The company had revenue of $0.34 million for the quarter, compared to analyst estimates of $2.67 million.

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), Amarin (AMRN), Vaxart (VXRT) and Agile Therapeutics (AGRX).

When did PhaseBio Pharmaceuticals IPO?

(PHAS) raised $66 million in an IPO on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

What is PhaseBio Pharmaceuticals' stock symbol?

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

How do I buy shares of PhaseBio Pharmaceuticals?

Shares of PHAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PhaseBio Pharmaceuticals' stock price today?

One share of PHAS stock can currently be purchased for approximately $0.00.

How much money does PhaseBio Pharmaceuticals make?

PhaseBio Pharmaceuticals (NASDAQ:PHAS) has a market capitalization of $29,914.80 and generates $818,000.00 in revenue each year. The company earns $-131,070,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis.

How can I contact PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The official website for the company is www.phasebio.com. The company can be reached via phone at (610) 981-6500 or via email at pmobley@nobleromans.com.

This page (NASDAQ:PHAS) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -